Clene Inc. focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN)therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis. The company also markets and distributes dietary supplements.
